EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights

Ashish Manne, Yonghua Bao, Ankur Sheel, Amir Sara, Upender Manne, Kannan Thanikachalam, Ashwini Esnakula, Timothy M Pawlik, Jordan M Cloyd, Susan Tsai, Anup Kasi, Ravi Kumar Paluri und 4 weitere

Frontiers in Oncology · 07.04.2025 · 15

DOI: 10.3389/fonc.2025.1544928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 07.04.2025. Verfasst von Ashish Manne und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United S…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We investigated the association between serum MUC5AC (sMUC5AC) levels and patient outcomes in individuals who underwent resection for pancreatic ductal adenocarcinoma (PDA), including those treated with neoadjuvant therapy (NAT) and those who had upfront surgery (UpS) followed by adjuvant therapy.

Methods

Serum samples from the Ohio State University biorepository collected from January 2010 to June 2021 were utilized. The human MUC5AC kit (NBP2-76703) was used to perform enzyme-linked immunoassays to measure sMUC5AC levels. Logistic regression, Cox regression models (univariate and multivariate), recurrence prediction, analysis of variance (ANOVA), t-tests, and Wilcoxon tests were used for statistical analysis.

Results

In the NAT cohort (n = 23), elevated sMUC5AC levels were significantly ( P < 0.05) associated with pathological treatment response, margin positivity, and residual disease. Among 21 patients who had an R0/R1 resection (R2 resection, n=2), higher sMUC5AC levels were associated with shorter progression-free survival (PFS) (HR: 1.64, P = 0.0006) and overall survival (OS) (HR: 1.6, P = 0.005) on univariate analysis. Multivariate models confirmed sMUC5AC as an independent predictor of PFS and OS alongside pathological differentiation and postoperative therapy. Patients with lower sMUC5AC levels had more favorable pathological characteristics, better treatment responses, and improved survival outcomes. These findings were consistent in the FOLFIRINOX subgroup (n = 17). In the UpS cohort (n = 17), post-resection sMUC5AC levels tend to be associated with PFS (P = 0.07) and OS ( P = 0.05). Combining sMUC5AC with Carbohydrate antigen (CA) 19-9 enhanced sensitivity (79%) and specificity (67%) to predict recurrence. Higher sMUC5AC levels were associated with earlier recurrence and poor survival outcomes, highlighting its utility in post-surgery risk stratification. Among patients with pre-treatment data (n = 11), sMUC5AC levels were significantly higher among patients with poorly differentiated tumors.

Conclusion

This study provides compelling evidence for the clinical utility of sMUC5AC as a prognostic biomarker among patients with resected PDA. Future large-scale studies are needed to validate these findings and establish standard thresholds for sMUC5AC integration into clinical practice.

Schlagwörter

Stichwörter der Autor:innen

FOLFIRINOXMUC5ACbiomarkerneoadjuvant therapypancreatic cancerpredictingprognostic markerserum MUC5AC

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
  • Clinical & Translational Science Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
  • Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Department of Pathology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
  • Department of Surgery, Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Manne, A., Bao, Y., Sheel, A., Sara, A., Manne, U., Thanikachalam, K., Esnakula, A., Pawlik, T. M., Cloyd, J. M., Tsai, S., Kasi, A., Paluri, R. K., Sherpally, D., Jeepalyam, S., Yu, L., & Yang, W. (2025). Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1544928

Vancouver

Manne A, Bao Y, Sheel A, Sara A, Manne U, Thanikachalam K, et al. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1544928

BibTeX
@article{Manne2025,
  author = {Manne, Ashish and Bao, Yonghua and Sheel, Ankur and Sara, Amir and Manne, Upender and Thanikachalam, Kannan and Esnakula, Ashwini and Pawlik, Timothy M and Cloyd, Jordan M and Tsai, Susan and Kasi, Anup and Paluri, Ravi Kumar and Sherpally, Deepak and Jeepalyam, Sravan and Yu, Lianbo and Yang, Wancai},
  title = {Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1544928}
}
Kostenlos starten →